Pharmacodynamics and pharmacokinetics of levofloxacin

Chemotherapy

Volumn 46, Issue SUPPL. 1, 2000, Pages 6-14

  Nightingale, Charles H ^a   Grant, Edward M ^a   Quintiliani, Richard ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

AUC MIC; Cost; Levofroxacin; Pharmacodynamics

Indexed keywords

AZITHROMYCIN; CEFUROXIME AXETIL; CIPROFLOXACIN; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; TOBRAMYCIN; TROVAFLOXACIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG COST; DRUG DISTRIBUTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0034014774     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048487     Document Type: Conference Paper

References (8)

1. Lacy MK, Lu W, Xu X, Tessier PR, Nicolau DP, Quintiliani R, Nightingale CH: Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672-677.
2. Lister PD, Sanders CC: Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. Br Soc Antimicrob Chemother 1999;43:79-86.
3. Nightingale CH: Determining outcomes in respiratory tract infections: Pathogen, patient, and antibiotic properties. Infect Med 1999; (special suppl):37-40.
4. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R: Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995;39:650-655.
5. Grant EM, Quintiliani R: Application of Population Pharmacokinetics and Surveillance Data to Predict AUC/MIC Ratios: A Monte Carlo Analysis. American Society of Health-System Pharmacists Mid-year Clinical Meeting, Orlando 1999.
6. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Wong FA, Corrado M: Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother 1998;42:1098-1104.
7. Thornsberry C, et al: Tracking Resistance in the United States Today, 1998-1999 (TRUST III report). San Francisco, ICAAC, 1999.
8. Richerson MA, Ambrose PG, Quintiliani R, Bui K, Nightingale CH: Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia. Infect Dis Clin Pract 1998;7:227-233.